Study Name:
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC). (KRASCENDO-1)
Study Dates:
September 23, 2024 - September 30, 2029
Study Location:
Nationwide
Sponsors:
F. Hoffmann-La Roche Ltd
https://clinicaltrials.gov/study/NCT06497556
